A Study Of PGN-EDO51 In Participants With Duchenne Muscular Dystrophy Amenable To Exon 51-Skipping Treatment
← catalyst calendarSponsored by PepGen Inc (industry) · PEPG — their whole pipeline →.
Phase
Phase 2
Status
Terminated
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
7actual
Sites
5
Country
Canada
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
PGN-EDO51 development terminated by Sponsor
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-01-03 | actual | When the study began enrolling |
| Primary completion | 2025-08-28 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-08-28 | actual | The whole study's end, after follow-up |
| First posted | 2023-10-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Duchenne Muscular Dystrophy
Intervention
- Drug: PGN-EDO51
Primary outcomes
what the primary-completion date above is the date OFAdverse events and serious adverse events (safety and tolerability of PGN-EDO51 in MAD period)
measured Baseline to Week 16
Adverse events and serious adverse events (long-term safety and tolerability of PGN-EDO51 in LTE period)
measured Baseline to Week 108
Permalink · PEPG's whole pipeline · Catalyst calendar · Every registered study · What changed